Arch Therapeutics, Inc. (ARTH)

USD 0.23

(31.81%)

Market Cap (In USD)

1.02 Million

Revenue (In USD)

75.72 Thousand

Net Income (In USD)

-6.98 Million

Avg. Volume

2055.00

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.17-9.0
PE
-
EPS
-
Beta Value
3.691
ISIN
US03939W2089
CUSIP
03939W109
CIK
1537561
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Terrence W. Norchi M.D.
Employee Count
-
Website
https://www.archtherapeutics.com
Ipo Date
2013-01-02
Details
Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. Its flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. The company was founded in 2006 and is based in Framingham, Massachusetts.